Skip Header

You are using a version of browser that may not display all the features of this website. Please consider upgrading your browser.
1 to 19 of 19  Show

Literature citations Results

Citation
Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma.

Kridel R., Meissner B., Rogic S., Boyle M., Telenius A., Woolcock B., Gunawardana J., Jenkins C., Cochrane C., Ben-Neriah S. et al.

Blood 119:1963-1971(2012) · Mapped (10)

The pre-B-cell receptor associated protein VpreB3 is a useful diagnostic marker for identifying c-MYC translocated lymphomas.

Rodig S.J., Kutok J.L., Paterson J.C., Nitta H., Zhang W., Chapuy B., Tumwine L.K., Montes-Moreno S., Agostinelli C., Johnson N.A. et al.

Haematologica 95:2056-2062(2010) · Mapped (62)

TBL1XR1/TP63: a novel recurrent gene fusion in B-cell non-Hodgkin lymphoma.

Scott D.W., Mungall K.L., Ben-Neriah S., Rogic S., Morin R.D., Slack G.W., Tan K.L., Chan F.C., Lim R.S., Connors J.M. et al.

Blood 119:4949-4952(2012) · Mapped (11)

Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations.

Will B., Zhou L., Vogler T.O., Ben-Neriah S., Schinke C., Tamari R., Yu Y., Bhagat T.D., Bhattacharyya S., Barreyro L. et al.

Blood 120:2076-2086(2012) · Mapped (6)

Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma.

Gunawardana J., Chan F.C., Telenius A., Woolcock B., Kridel R., Tan K.L., Ben-Neriah S., Mottok A., Lim R.S., Boyle M. et al.

Nat. Genet. 46:329-335(2014) · Mapped (4)

Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS.

Barreyro L., Will B., Bartholdy B., Zhou L., Todorova T.I., Stanley R.F., Ben-Neriah S., Montagna C., Parekh S., Pellagatti A. et al.

Blood 120:1290-1298(2012) · UniProtKB (1) · Mapped (2)

MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy.

Savage K.J., Johnson N.A., Ben-Neriah S., Connors J.M., Sehn L.H., Farinha P., Horsman D.E., Gascoyne R.D.

Blood 114:3533-3537(2009) · Mapped (61)

Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing.

Morin R.D., Mungall K., Pleasance E., Mungall A.J., Goya R., Huff R.D., Scott D.W., Ding J., Roth A., Chiu R. et al.

Blood 122:1256-1265(2013) · Mapped (3)

Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition.

Ennishi D., Takata K., Beguelin W., Duns G., Mottok A., Farinha P., Bashashati A., Saberi S., Boyle M., Meissner B. et al.

Cancer Discov 9:546-563(2019) · Mapped (18)

Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival.

Johnson N.A., Savage K.J., Ludkovski O., Ben-Neriah S., Woods R., Steidl C., Dyer M.J., Siebert R., Kuruvilla J., Klasa R. et al.

Blood 114:2273-2279(2009) · Mapped (70)

Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma.

Twa D.D., Chan F.C., Ben-Neriah S., Woolcock B.W., Mottok A., Tan K.L., Slack G.W., Gunawardana J., Lim R.S., McPherson A.W. et al.

Blood 123:2062-2065(2014) · Mapped (5)

Genomic Alterations in CIITA Are Frequent in Primary Mediastinal Large B Cell Lymphoma and Are Associated with Diminished MHC Class II Expression.

Mottok A., Woolcock B., Chan F.C., Tong K.M., Chong L., Farinha P., Telenius A., Chavez E., Ramchandani S., Drake M. et al.

Cell Rep 13:1418-1431(2015) · Mapped (9)

Genetic profiling of MYC and BCL2 in diffuse large B-cell lymphoma determines cell-of-origin-specific clinical impact.

Ennishi D., Mottok A., Ben-Neriah S., Shulha H.P., Farinha P., Chan F.C., Meissner B., Boyle M., Hother C., Kridel R. et al.

Blood 129:2760-2770(2017) · Mapped (70)

Genetic inactivation of TRAF3 in canine and human B-cell lymphoma.

Bushell K.R., Kim Y., Chan F.C., Ben-Neriah S., Jenks A., Alcaide M., Fornika D., Grande B.M., Arthur S., Gascoyne R.D. et al.

Blood 125:999-1005(2015) · Mapped (3)

Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma.

Morin R.D., Mendez-Lago M., Mungall A.J., Goya R., Mungall K.L., Corbett R.D., Johnson N.A., Severson T.M., Chiu R., Field M. et al.

Nature 476:298-303(2011) · Mapped (8)

Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

Johnson N.A., Slack G.W., Savage K.J., Connors J.M., Ben-Neriah S., Rogic S., Scott D.W., Tan K.L., Steidl C., Sehn L.H. et al.

J. Clin. Oncol. 30:3452-3459(2012) · Mapped (70)

Comprehensive characterization of programmed death ligand structural rearrangements in B-cell non-Hodgkin lymphomas.

Chong L.C., Twa D.D., Mottok A., Ben-Neriah S., Woolcock B.W., Zhao Y., Savage K.J., Marra M.A., Scott D.W., Gascoyne R.D. et al.

Blood 128:1206-1213(2016) · Mapped (5)

An RCOR1 loss-associated gene expression signature identifies a prognostically significant DLBCL subgroup.

Chan F.C., Telenius A., Healy S., Ben-Neriah S., Mottok A., Lim R., Drake M., Hu S., Ding J., Ha G. et al.

Blood 125:959-966(2015) · Mapped (1)

Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis.

Cheung K.J., Johnson N.A., Affleck J.G., Severson T., Steidl C., Ben-Neriah S., Schein J., Morin R.D., Moore R., Shah S.P. et al.

Cancer Res. 70:9166-9174(2010) · Mapped (6)

1 to 19 of 19  Show
UniProt is an ELIXIR core data resource
Main funding by: National Institutes of Health

We'd like to inform you that we have updated our Privacy Notice to comply with Europe’s new General Data Protection Regulation (GDPR) that applies since 25 May 2018.

Do not show this banner again